Pilot study of COVID+ pts treated with antiviral therapy PLUS either Baricitinib or HCQ x2wks shows no changes in clinical/lab outcomes with HCQ/v but better outcomes with Bari for death (0 v 4), CRP *8-->1mg/dl) & discharges (55% v8%) compared to HCQ https://t.co/sTqYHMNOGG
Links:
Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact
https://bit.ly/2xqjyIB
May-01-2020
